About This Manual

What this site is

Telehealth PT-141 is an independent editorial project that publishes summaries of the peer-reviewed research literature on bremelanotide (PT-141) and of the regulatory framework that governs its prescribing by telemedicine. We are not a clinic. We do not employ clinicians, and we do not provide medical advice, evaluation, consultation, diagnosis, or treatment. We do not manufacture, sell, or distribute any product, including any bremelanotide preparation. Our work is editorial commentary on publicly available science and on publicly available federal and state regulatory documents.

The domain name includes the word 'telehealth' because the site's editorial focus is the telehealth pathway for bremelanotide — how qualified clinicians evaluate and prescribe it remotely under federal and state law. The modifier describes our editorial position relative to the literature. It is not a claim that we provide telehealth services.

Editorial standards and sourcing

Every quantitative claim on this site is sourced to a published study or regulatory document. Our priority sources, in approximate order, are: the FDA-approved prescribing information (DailyMed and accessdata.fda.gov); peer-reviewed clinical trials (PubMed-indexed journals); systematic reviews and professional society guidelines (ICSM, ACOG, ISSWSH, ISSM); the National Library of Medicine's LiverTox monograph series; and HHS / Telehealth.gov for regulatory baseline. We do not cite product marketing pages, vendor materials, or social-media posts. We do not cite preprints unless the topic specifically demands current-but-uncommitted research and the preprint is clearly labeled as such.

The site does not link to commercial vendors of bremelanotide, compounded preparations, or research peptides. The site does not link to specific telehealth platforms. The references page links only to the primary scientific and regulatory sources that underwrite the editorial summaries.

What we do not claim

We do not employ doctors, pharmacists, nurses, nurse practitioners, or any other healthcare staff. The phrase 'qualified clinician' or 'state-licensed clinician' on this site refers to the kind of clinician who would perform the evaluation in the published practice frame — not to anyone on staff with us. We have no clinical staff because we are not a clinical operation. We do not maintain a clinic, a dispensing pharmacy, or any patient-facing service.

The site does not, and will not, sell bremelanotide, sell access to a prescribing clinician, refer patients to specific telehealth platforms, or operate any kind of intake or evaluation. This site is an independent editorial reference — a digest of publicly available scientific and regulatory documents — and nothing here constitutes medical advice or a clinical recommendation.

On the FDA-approved product vs. compounded vs. research peptides

We distinguish carefully throughout the manual between the FDA-approved bremelanotide product (a specific 1.75 mg subcutaneous autoinjector manufactured under federal oversight) and other preparations marketed under the name 'PT-141'. The clinical data, pharmacokinetic profile, safety profile, and dosing guidance summarized on this site applies to the FDA-approved product. Compounded preparations are a separate regulatory category, evaluated under the FDA's evolving compounding-category framework. Research peptide vials are not FDA-evaluated products of any kind. This distinction matters and is noted on every page where the topic arises.